| Customization: | Available |
|---|---|
| Transport Package: | Drum |
| Specification: | 99% |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Rivaroxaban, marketed under the brand name Xarelto, is an oral direct factor Xa inhibitor used in the treatment and prevention of various thromboembolic disorders. It is the first of a new class of oral anticoagulants (NOACs) that act as selective and competitive inhibitors of factor Xa, an enzyme in the coagulation cascade that leads to the formation of blood clots.
Mechanism of Action: Rivaroxaban directly and reversibly binds to factor Xa, preventing the conversion of prothrombin to thrombin and thus inhibiting both free and clot-bound factor Xa. This action blocks the amplification of the coagulation cascade and prevents thrombus formation. Unlike warfarin, rivaroxaban does not require antithrombin III for its anticoagulant effect and does not have a dependency on dietary vitamin K for its activity.
Indications: Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients undergoing total hip or knee replacement surgery. It is also used for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Additionally, it is prescribed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and/or PE. Rivaroxaban has also been approved for use in combination with aspirin to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease.
){kind=link}